trial

Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone

NCTId NCT01173874
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 120 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2013-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2010-07
Primary completion
2013-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Cognitive Remediation

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor

Investigators

2
Jeffrey A Lieberman, M.D.Principal Investigator
Zafar Sharif, M.D.Principal Investigator

Sites

16 total
Granada Hills, United StatesOrange, United StatesNew Haven, United StatesMiami, United StatesAugusta, United StatesChicago, United StatesChicago, United StatesIndianapolis, United StatesBoston, United StatesMinneapolis, United StatesColumbia, United StatesNew York, United States

Linked catalysts

1
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffect — primary completion2013-10

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE3
Primary Completion Date
2013-10
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Remediation
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jeffrey A Lieberman, M.D.
person
Zafar Sharif, M.D.
person